Repositioning Candidate Details
| Candidate ID: | R1601 |
| Source ID: | DB16620 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Methopterin |
| Synonyms: | 10-methylfolic acid; 10-methylpteroylglutamic acid; alpha-Methopterin; Methopterine; Methotrexate related compound C; N10-methylfolic acid; N10-methylpteroylglutamic acid |
| Molecular Formula: | C20H21N7O6 |
| SMILES: | CN(CC1=CN=C2N=C(N)NC(=O)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O |
| Structure: |
|
| DrugBank Description: | Methopterin is thought to have effects on osteoclasts and to inhibit inflammatory bone destruction. |
| CAS Number: | 2410-93-7 |
| Molecular Weight: | 455.431 |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Methopterin has been shown to inhibit the proliferation, activation, and bone resorption action of osteoclasts, and induce the apoptosis of osteoclasts, likely contributing to the ability of methopterin to inhibit inflammatory bone destruction. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S13 | Anti-apoptosis | hepatocyte apoptosis; hepatic autophagy; apoptosis | Pan-caspase inhibitor | Emricasan | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|